Why Large CROs and CDMOs Should Embrace Research Orchestration Platforms — Even with Existing Pharma Clients

This blog post was written by Kevin Lustig, Cofounder and CEO of Scientist.com.

For many large CROs and CDMOs, the rise of research orchestration platforms raises an understandable question: if we already have strong direct relationships with pharma clients, why should we also engage through a platform like Scientist.com?

It is a fair question. And the answer says a lot about where the industry is headed.

For years, outsourcing success in life sciences was driven primarily by scientific expertise, delivery, reputation and trusted relationships. Those factors still matter enormously. But today they are no longer enough on their own. Increasingly, the providers that win the most business are not just those with the strongest capabilities. They are the ones that are easiest for customers to engage, onboard, govern, scale and manage across the enterprise.

That is why platforms like Scientist.com matter.

This is not about displacing provider relationships. It is about modernizing how those relationships operate inside increasingly complex pharma organizations.

Pharma’s operating model has changed

Over the last two decades, large pharmaceutical companies have dramatically increased the sophistication of their external research operations. They now manage vast networks of CROs, CDMOs, specialty labs, consultants and technology providers across geographies, business units and therapeutic areas. As outsourcing has expanded, so has the need for structure.

Scientists still want the best provider for the job. Procurement still wants value and speed. Compliance still wants consistency. Finance still wants control and visibility. Legal still wants standardized processes. And executive leadership wants all of it to work together without slowing research down.

That pressure has given rise to a new reality: pharma companies are not just buying science anymore. They are buying science through systems.

In that environment, being a preferred provider is important, but being easy to work with inside the client’s preferred operating model is becoming just as important.

The platform is not the relationship. It is the infrastructure around the relationship.

Some providers initially view platforms as an extra layer between themselves and their customer. In practice, the opposite is often true.
The best platforms do not replace trusted CROs and CDMOs. They make it easier for pharma clients to work with them. They reduce the friction that often exists around the relationship rather than within it.

That friction is familiar to anyone in the industry: fragmented intake, unclear scoping, slow stakeholder alignment, duplicative compliance reviews, lengthy contracting cycles, inconsistent purchasing workflows and limited visibility across internal teams. Even when a pharma client already knows exactly which provider they want to use, the path from interest to project start can still be slower and more painful than it should be.

Scientist.com helps solve that problem. By streamlining intake, supporting scoping, standardizing compliance workflows, and helping clients move more efficiently from request to proposal to launch, the platform makes existing provider relationships easier to activate. That benefits the client, but it also benefits the provider. Less friction in the buying process means more projects move forward.

Ease of engagement is now a competitive advantage

This is one of the most important shifts happening in outsourced R&D.

Large providers have historically competed on scientific depth, geographic reach, quality systems and customer service. They still do. But in a world where pharma organizations are trying to move faster with better governance, operational fit has become a competitive differentiator.

If one provider is scientifically excellent but cumbersome to engage, and another is scientifically excellent and simple to activate through the client’s preferred platform, that difference matters. It can shape award decisions, speed to start, repeat business and overall share of wallet.
In other words, ease of engagement is no longer an administrative detail. It is part of the value proposition.

Platforms can expand existing accounts, not just manage them

Perhaps the most overlooked opportunity for large CROs and CDMOs is this: platforms are not only useful for administering work you already have. They can help you grow within customers you already serve.

In many pharma organizations, provider relationships are narrower than they appear. A CRO may be deeply embedded with one therapeutic team, one site, one function or one region while remaining largely invisible to other parts of the same enterprise. A CDMO may be well known in one program area but not considered for adjacent needs elsewhere in the business.

A platform like Scientist.com helps expose provider capabilities more broadly across the customer organization. It can surface your services to new stakeholders, new research teams, new sites and new categories of demand that might otherwise remain out of reach. That turns the platform into more than a workflow tool. It becomes a mechanism for internal account expansion.

For providers looking to grow key accounts, that matters.

One connection can create many commercial opportunities

There is also a broader strategic benefit.

Working through Scientist.com is not just about supporting one customer at a time. It can also create leverage across many customers. One integration and one contractual pathway can provide access to the broad base of pharma and biotech companies already using the platform. That gives providers an additional commercial channel without requiring a separate bespoke setup for every opportunity.

For business development teams, that means faster access to relevant demand. For sales leadership, it means another route to qualified opportunities. For the organization as a whole, it means the platform can serve both operational and growth goals at once.

That combination is powerful. Providers are not being asked to trade relationship strength for platform participation. They are being given a way to scale relationship value more efficiently.

The shift is being driven by customers

Most importantly, this is where pharma is going.

Large life science companies are increasingly standardizing the way they source and manage external research. They want providers who can work effectively within the systems, controls and workflows they have chosen. That does not mean they care less about relationships. It means they want those relationships to function within a more scalable and governable framework.

Providers that understand this shift will be better positioned to thrive. They will be easier to buy from, easier to onboard, easier to scale and easier to reuse across the enterprise. Those are all qualities customers reward.

Providers that resist may still retain strong relationships for some time. But over time, resistance to the client’s preferred way of working can start to look like friction. And friction is rarely a winning strategy.

A stronger position, not a weaker one

The key point is simple: using Scientist.com does not diminish the role of the CRO or CDMO. It strengthens their position inside the client’s operating environment.

You still own the science. You still build the trust. You still deliver the results. What the platform changes is the infrastructure around that work. It makes it easier for the customer to engage, easier for internal stakeholders to align and easier for projects to move forward.

That is why the most forward-looking providers do not see research orchestration platforms as a threat. They see them as a force multiplier.

As pharma continues to modernize outsourced R&D, the winners will not only be the providers with the best science. They will be the providers that combine scientific excellence with operational compatibility, commercial responsiveness and enterprise-scale ease of engagement.

That is exactly the kind of advantage Scientist.com is built to deliver.